Treatment of Parkinsons disease and related disorders by novel formulations of the combination carbidopa-levodopa

Plasma levodopa level treated with levodopa in combination with carbidopa or benserazide in Parkinsons disease. Journal of Pharmacological Sciences 94(Supplement 1): 118P, 2004

First experiences of the new triple combination of levodopa/carbidopa/entacapone in the treatment of patients with Parkinsons disease. European Journal of Neurology 10(Supplement 1): 163-164, 2003

New triple combination of levodopa/carbidopa/entacapone is a preferred treatment in patients with Parkinsons disease. Neurology 60(5 Supplement 1): A289, March 11, 2003

Early-morning akinesia in Parkinsons disease Effect of standard carbidopa/levodopa and controlled-release carbidopa/levodopa. Neurology 45(4 SUPPL 4): A252, 1995

Safety, tolerance, pharmacokinetics and pharmacodynamics of BMS-204756 administered in combination with levodopa/carbidopa to patients with Parkinsons Disease. Society for Neuroscience Abstracts 27(1): 529, 2001

Safety, tolerability, pharmacokinetics and pharmacodynamics of BMS-204756 administered in combination with levodopa/carbidopa to Parkinsons disease patients. Society for Neuroscience Abstracts 26(1-2): Abstract No -818 9, 2000

Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clinical Neuropharmacology 32(4): 189-192, 2009

Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. European Neurology 53(4): 197-202, 2005

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study. Journal of Neural Transmission 117(3): 333-342, 2010

Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). Journal of Clinical Pharmacology 55(9): 995-1003, 2016

Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. Annals of PharmacoTherapy 36(2): 225-230, 2002

Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease. Diseases of the Nervous System 38(8): 605-608, 1977

Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications. Clinical Neuropharmacology 36(3): 84-91, 2014

Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination. Neurologia 20(4): 180-188, 2005

Levodopa/Carbidopa solution in advanced Parkinsons disease patients. Atencion Farmaceutica 1(2): 196-197, March-April, 1999